Departamento de Bioquimica and Center for Free Radical and Biomedical Research (CEINBIO), Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay.
Adv Exp Med Biol. 2019;1161:233-241. doi: 10.1007/978-3-030-21735-8_18.
Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease involving motor neuron (MN) degeneration in the spinal cord, brain stem and primary motor cortex. The existence of inflammatory processes around MN and axonal degeneration in ALS has been shown. Unfortunately, none of the successful therapies in ALS animal models has improved clinical outcomes in patients with ALS. Therefore, the detection of blood biomarkers to be used as screening tools for disease onset and progression has been an expanding research area with few advances in the development of drugs for the treatment of ALS. In this review, we will address the available data analyzing regarding the relationship of lipid metabolism and lipid derived- products with ALS. We will address the advances on the studies about the role that lipids plays at the onset, progression and lifespan extension of ALS patients.
肌萎缩侧索硬化症（ALS）是一种多因素神经退行性疾病，涉及脊髓、脑干和初级运动皮层中的运动神经元（MN）退化。已经证明 ALS 中存在 MN 周围的炎症过程和轴突退化。不幸的是，在 ALS 动物模型中成功的治疗方法都没有改善 ALS 患者的临床结果。因此，检测血液生物标志物作为疾病发病和进展的筛查工具一直是一个不断扩展的研究领域，而在开发治疗 ALS 的药物方面进展甚微。在这篇综述中，我们将讨论关于脂质代谢和脂质衍生产物与 ALS 关系的现有数据。我们将讨论关于脂质在 ALS 患者发病、进展和寿命延长中所起作用的研究进展。
